" said Dr. Ting Xu, Chairman of the Board and CEO of Alphamab Oncology. "We are pleased to see that the phase I clinical trial of KN046 in Australia is progressing well and has achieved the anticipated therapeutic dose. We expect
KN026 is an anti-Her-2 heterodimer, based on the company’s proprietary Fc based bispecific platform (CRIB) with the same format and size of natural IgG antibody. It has demonstrated an excellent pre-clinical profile in binding affinity, efficacy, safety, and PK. KN026 showed better efficacy...
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of world-class innovative therapeutics for cancer treatment. With multiple in-house proprietary platforms, including bispecifics, protein engineering and antibody screening,...